AbbVie Reports Full-Year and Fourth-Quarter 2019 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
AbbVie (ABBV) Climbs on Market Open, Up 2.4%
February 10, 2020 9:41 AM ESTAbbVie (NYSE: ABBV) Climbs on Market Open, Up 2.4%
... MoreAbbvie (ABBV) PT Raised to $97 at Piper Sandler
February 7, 2020 1:23 PM ESTPiper Sandler analyst Christopher Raymond raised the price target on Abbvie (NYSE: ABBV) to $97.00 (from $95.00) while maintaining a Overweight rating following results.
... MoreAbbVie (ABBV) Sees Strong Gains Post-EPS
February 7, 2020 12:39 PM ESTAbbVie (NYSE: ABBV) seeing strong gains following results this morning. Shares up 5.5%.
... MoreAbbVie (ABBV) Tops Q4 EPS by 2c, FY20 EPS Guidance Beats
February 7, 2020 7:44 AM ESTAbbVie (NYSE: ABBV) reported Q4 EPS of $2.21, $0.02 better than the analyst estimate of $2.19. Revenue for the quarter came in at $8.7 billion versus the consensus estimate of $8.7 billion.
GUIDANCE:
AbbVie sees FY2020 EPS of $9.61-$9.71, versus the consensus of... More
